Search the Newsreel

Incyte Corp (INCY) R&D chief sells 10,803 shares under Rule 10b5-1 plan

Incyte Corp's President, Global Head of R&D, Pablo J. Cagnoni, sold 10,803 shares of common stock at $120.04 per share on August 12, 2026, under a Rule 10b5-1 trading plan. Following this transaction, Cagnoni directly holds 194,001 shares, which includes 183,200 shares from unvested …

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme's proprietary ENHANZE drug delivery technology, …

Incyte Sales Growth Drives Share Price Gains

INCY discovers, develops, and sells proprietary therapeutics focused on hematology, oncology, inflammation, and autoimmunity. The company's second-quarter fiscal 2026 earnings report, INCY showed $1.67 billion in quarterly revenue (a 38% year-over-year gain) led by Jakafi ($817 million) and Opzelura ($450 million), net sales of …

Insight Wealth Strategies LLC Acquires New Position in Incyte Corporation $INCY

Insight Wealth Strategies LLC has acquired a new stake of 62,175 shares in Incyte Corporation, valued at approximately $7.1 million, during the second quarter. Incyte reported strong quarterly earnings, beating analyst estimates with an EPS of $3.09 and revenue of $1.67 billion. Despite mixed …

How Regeneron Pharmaceuticals Went From Cheaper Than Incyte To The Pricier Stock

Regeneron Pharmaceuticals (REGN) now trades at a premium compared to Incyte (INCY), a reversal from a year ago. Regeneron's premium is attributed to its scale, blockbuster drugs like Dupixent and EYLEA HD, and a deep pipeline of approximately 50 clinical programs, despite slower growth …

Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages

Incyte Corporation (NASDAQ:INCY) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $120.40. The company recently reported strong quarterly earnings, beating estimates with an EPS of $3.09 and revenue of $1.67 billion, a 37.7% increase year-over-year. Despite a …

Incyte Corporation (INCY) Stock Analysis: Strong Revenue Growth and Robust Pipeline Fuel Investor Interest

Incyte Corp (INCY) R&D head sells 10,640 shares in plan trade

Pablo J. Cagnoni, President and Global Head of R&D at Incyte (INCY), sold 10,640 shares of common stock at $122.69 per share on August 5, 2026. This transaction was executed under a Rule 10b5-1 trading plan. Following the sale, Cagnoni retains 204,804 shares, which …

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Corporation announced that it granted restricted stock unit awards and stock option awards to 24 new employees as an inducement to their employment. These awards, totaling 21,556 shares in RSUs and options for 18,172 shares, were made under the company's 2024 Inducement Stock …

24 New Incyte Hires Receive Stock Units Vesting in Four Steps

Incyte Corporation (Nasdaq: INCY) announced it granted restricted stock unit awards for 21,556 shares and stock option awards for 18,172 shares to 24 new employees. These awards, granted under the 2024 Inducement Stock Incentive Plan with a vesting commencement date of August 3, 2026, …

Incyte Corp (INCY) EVP sells 2,207 shares after option exercise

Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp (INCY), exercised 2,207 employee stock options at $106.47 per share and subsequently sold the same number of common shares at $123.99 per share on August 5, 2026. These transactions were executed under a …

Oppenheimer raises Incyte stock price target on Vega acquisition

Oppenheimer has increased its price target for Incyte Corp. (NASDAQ:INCY) to $107 from $90, maintaining an Outperform rating after Incyte acquired Vega Therapeutics. The acquisition adds VGA039, a Phase 3-ready Protein S modulator for von Willebrand disease, which Oppenheimer believes could be a significant …

Incyte Corp. stock outperforms competitors despite losses on the day

Incyte Corp. (INCY) shares decreased by 1.19% to $118.38 on Thursday, despite a broader market decline where the S&P 500 Index fell 0.18% and the Dow Jones Industrial Average dropped 0.85%. This marks the second consecutive day of losses for Incyte, yet the stock …

REGN or INCY: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. …

Incyte (INCY) Could Be 5% Overvalued Following Opzelura Approval And Higher Guidance

Incyte Corp (INCY) EVP sells 47,954 shares after exercising options

Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte (INCY), exercised stock options for 45,767 shares and subsequently sold 47,954 shares of common stock on July 31 and August 3, 2026, through a Rule 10b5-1 trading plan. The sales amounted to approximately $5.73 …

Incyte Corp (INCY) R&D head sells 15,888 shares, retains 215,444

Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp (INCY), sold 15,888 shares of the company's common stock at $119.70 per share on July 31, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Cagnoni directly …

Incyte Corp. stock outperforms competitors on strong trading day

Incyte Corp. (INCY) shares rose 1.83% to $120.60, outperforming the broader market during a strong trading session where the S&P 500 and Dow Jones also saw significant gains. This increase broke a four-day losing streak for the company's stock.

Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company …

INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $150

HC Wainwright & Co. has reiterated its Buy rating for Incyte (INCY), maintaining a price target of $150.00, indicating confidence in the company's future despite its current overvaluation according to GuruFocus. Incyte, a biotechnology company with a strong GF Score of 87/100, is considered …

H.C. Wainwright reiterates Incyte stock rating on JAK inhibitor data

H.C. Wainwright has reiterated a Buy rating and a $150 price target for Incyte (NASDAQ: INCY) following the release of clinical trial results for a competing JAK inhibitor therapy by Pfizer. Despite competitor data, the firm maintains its estimates for Incyte, anticipating that upcoming …

Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating

Leerink Partners has updated its price target for Incyte (INCY) to $155, an increase from the previous $131, while reiterating an Outperform rating on the stock. This adjustment reflects a continued positive outlook for the company from the analyst firm. Despite the upgrade, the …

Leerink Partners Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price

Incyte Corporation $INCY Shares Acquired by Pacer Advisors Inc.

Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as …

European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)

In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of …

Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. …

Incyte Corporation $INCY Shares Sold by Glenmede Trust Co. NA

Novacyt (NCYT) Q2 2024 Earnings Report - Results, Call & Slides

Incyte Corp. stock underperforms Friday when compared to competitors

Incyte Corp. (INCY) stock fell 2.82% to $119.52 on Friday, marking its third consecutive day of losses. This underperformance occurred despite a strong trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains.

Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

Incyte Corporation reported strong Q2 2026 results with a 38% year-over-year increase in total revenue, reaching $1.67 billion, and significant growth in its core business excluding Jakafi. Key strategic milestones included regulatory approvals and the acquisition of a new hematology asset. Despite challenges such …

INCY|Incyte Corp|Price:123.150|Chg%:-3.950

This article provides a comprehensive stock analysis of Incyte Corp (INCY) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The company's stock is rated as "Buy" by analysts with an expected upward trend in the medium …

Incyte Corp (1INCY) Q4 2023 Earnings Report - Results, Call & Slides

Incyte Corp (1INCY) released its Q4 2023 earnings report, detailing an actual EPS of €0.92, missing the consensus of €1.00 by -€0.08. Despite the EPS miss, the company's actual revenue of €880.33M beat the expected revenue of €871.11M, showing a year-over-year revenue growth of …